Tag: IMMUNOTHERAPY

"Bispecific Antibody CTX-8371 Research"

Compass Therapeutics Announces Publication of CTX-8371 Preclinical Data in OncoImmunology, its Bispecific Antibody Checkpoint Inhibitor, now Advancing to First-in-Human Clinical Trial

Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, announced the publication of a peer-reviewed article titled, “A bispecific anti-PD-1 and…